Preclinical studies have shown that pathways such as the Bcl-2, IL-1β, NT-3 and the MAPK pathway that are also involved in miRNA dysregulation may also be promising new horizons for diagnosis and treatment of experimental as well as clinical epilepsy. Here, IL1B is linked to epilepsy.